In this segment, Dr. Alexander Spira and Dr. Edward Kim focus on the importance of adverse event management in patients receiving adjuvant EGFR tyrosine kinase inhibitors for early-stage EGFR-mutated nonโsmall cell lung cancer (NSCLC). Dr. Kim discusses common toxicities associated with EGFR-TKIs, including dermatologic effects, diarrhea, and fatigue, and emphasizes the need for proactive monitoring and early intervention. The conversation highlights practical strategies such as patient education, routine follow-up, and timely use of supportive care measures to help mitigate side effects. Dr. Kim also underscores the importance of maintaining dose intensity whenever possible while using dose modifications appropriately to manage tolerability. By addressing adverse events early and effectively, clinicians can help patients remain on therapy and complete the intended duration of treatment. This segment reinforces the critical role of toxicity management in supporting adherence and optimizing outcomes in EGFR-mutated NSCLC.
